רקע כהה למעלה

CorNeat EverPatch 

The first synthetic and nondegradable tissue substitute for ophthalmic surgeries

About Ophthalmic Reconstructive Surgery

Reconstructive surgery of the eye takes place following irreparable damage to the eye’s integrity. Such damage can result following trauma, iatrogenic damage (damage caused unintentionally during a previous surgical procedure) or as a result of an inflammatory/connective tissue disease process. In these instances, the tissue can incur such damage that direct and immediate closure becomes impossible making patching the area with preserved and processed tissue the only treatment option.

Surgery

CorNeat KPro

רקע כהה למעלה

CorNeat EverPatch Advantages 

Everlasting 

 Inert and non-degradable material –

Bio-mechanical integration coupled with a minor and progressively subsiding, inflammatory response
 ​

Ease of

Handling

 Extremely easy to handle and suture

-

Elastic and durable (cannot be torn by the sutures)
 ​

Safe 

Synthetic and therefore cannot carry or transmit disease 

Cost-

Effective 

Reduces operating time and eye bank costs

-

Eliminates complexities related to the transportation and storage of biological materials

-

Readily available, off-the-shelf, device 
 ​

Aesthetic 

Translucent when wet

Hardly visible when implanted 

subconjunctivally

Eye contact4_Shutterstock.jpg

CorNeat EverPatch

The CorNeat EverPatch (scleral patch) is the first inert, synthetic and non-degradable tissue substitute for use in ophthalmic surgeries. The CorNeat EverPatch replaces the use of human tissue and degradable collagen patches for covering and concealing implants such as glaucoma drainage devices and sealing the eye in cases of missing tissue.   
 
The CorNeat EverPatch is composed of a non-woven, polymer matrix, which imitates the extracellular matrix, stimulating cellular colonization and integration with the surrounding tissue. 

Indications 

Covering irritating implants such as in glaucoma tube shunts or exposed sutures, displacing the need for preserved tissue/collagen. 

Covering tissue gaps/weaknesses, resulting either from traumatic, disease related or iatrogenic damage.

Eye contact3_Shutterstock.jpg
רקע כהה למעלה

Regulatory Path

The first-in-human (FIH) clinical trial for the CorNeat EverPatch took place on December 2020. The surgery was conducted by Dr. Ike Ahmed at the Prism Eye Institute in Toronto, Canada. Clinical trials are also taking place in Kenya and France. The trials are geared toward obtaining a CE marking during 2021. CorNeat Vision plans to extend the solution to the US market as a second step and work toward FDA approval. The exact FDA path will be coordinated with authorities during 2021.

Clinical sites:

Canada, Ontario

Prism Eye Institute

Status: Recruiting

Contact: Ayda Shahidi l tel. +1-905-456-3937 ext. 267 l e-mail: ayda.shahidi@prismeye.ca

Canada, Ontario

UHN – University Health Network – Toronto Western Hospital

Status: Recruiting

Contact: Olivera Sutakovic e-mail: olivera.sutakovic@uhn.ca

 

France, Paris

Hospital Foundation Adolphe De Rothschild

Status: Recruiting

Contact: Patrick Vachey l e-mail: pvachey@for.paris 

 

Kenya, Mombasa

Kwale Eye Hospital

Status: Recruiting

Contact: Helen Roberts l e-mail: eyeskwale@africaonline.co.ke

Kenya, Nairobi

Kenyatta National Hospital

Status: Recruiting

Contact: Lily Nyamai e-mail: lilynyamai@gmail.com

Kenya, Nairobi

Lions SightFirst Hospital

Status: Recruiting

Contact: Lily Nyamai l e-mail: lilynyamai@gmail.com

 

The plans above are subject to regulatory approvals and requirements.

For more information about clinical trials please visit clinicaltrials.gov.

 

Product Animation